Ligand Pharmaceuticals (LGND) partner GlaxoSmithKline (GSK) announced Monday morning that the FDA approved PROMACTA for the treatment of thrombocytopenia in patients with chronic hepatitis C.
Ligand Pharmaceuticals has spiked to the upside following a slightly delayed opening and is currently higher by 2.61 at $19.28. The stock is now challenging the highs of the year, trading at a 3-month high.
by RTT Staff Writer
For comments and feedback: email@example.com